BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 10529323)

  • 1. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
    Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of low-molecular-weight heparin and unfractionated heparin in the treatment of unstable angina].
    Godoy I; Herrera C; Zapata C; Kunstmann S; Abufhele A; Corbalán R
    Rev Med Chil; 1998 Mar; 126(3):259-64. PubMed ID: 9674294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy of once daily parnaparin and unfractionated heparin in unstable angina pectoris: PRIME CARE study.
    PRIME CARE Study Investigators Group
    Indian Heart J; 2005; 57(6):648-54. PubMed ID: 16521631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of the antithrombotlic effect and safety between intravenous nadroparin and unfractionated heparin in patients undergoing percutaneous coronary intervention].
    Zhu JH; Qiu YG; Chen JZ; Zhang FR; Fu GS; Shen FR; Huang WJ; Wang JA; Zhao LL; Tao QM; Zheng LR
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Apr; 33(4):335-9. PubMed ID: 15932664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
    Cohen M; Demers C; Gurfinkel EP; Turpie AG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KA; Premmereur J; Bigonzi F
    N Engl J Med; 1997 Aug; 337(7):447-52. PubMed ID: 9250846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability of percutaneous coronary interventions in patients receiving nadroparin calcium for unstable angina or non-Q-wave myocardial infarction: the Angiofrax study.
    Bassand JP; Berthe C; Bethencourt A; Bolognese L; Wójcik J;
    Curr Med Res Opin; 2003; 19(2):107-13. PubMed ID: 12740154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
    Salvioni A; Casilli F; Assanelli E; Grazi M; Marenzi G; Guazzi MD
    Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs.
    Jun L; Arnout J; Vanhove P; Dol F; Lormeau JC; Herbert JM; Collen D; Van de Werf F
    Coron Artery Dis; 1995 Mar; 6(3):257-63. PubMed ID: 7788040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group.
    Charbonnier BA; Fiessinger JN; Banga JD; Wenzel E; d'Azemar P; Sagnard L
    Thromb Haemost; 1998 May; 79(5):897-901. PubMed ID: 9609216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ESSENCE trial results: breaking new ground. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events.
    Demers C
    Can J Cardiol; 1998 Aug; 14 Suppl E():15E-19E. PubMed ID: 9779028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction.
    Baird SH; Menown IB; Mcbride SJ; Trouton TG; Wilson C
    Eur Heart J; 2002 Apr; 23(8):627-32. PubMed ID: 11969277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A meta-analysis of controlled clinical trials comparing low-molecular weight heparins with unfractionated heparin in unstable angina.
    Malhotra S; Karan RS; Bhargava VK; Pandhi P; Grover A; Sharma YP; Kumar R
    Indian Heart J; 2001; 53(2):197-202. PubMed ID: 11428477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemostatic activation under anticoagulant treatment: a comparison of unfractionated heparin vs. nadroparin in the treatment of proximal deep vein thrombosis.
    Stricker H; Marchetti O; Haeberli A; Mombelli G
    Thromb Haemost; 1999 Oct; 82(4):1227-31. PubMed ID: 10544903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Low-molecular weight heparin and acute coronary syndrome: theoretical background and its use in clinical practice].
    Ottani F; Ferrini D; Di Pasquale G; Galvani M
    Ital Heart J Suppl; 2001 Sep; 2(9):958-71. PubMed ID: 11675833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-molecular-weight heparin for the treatment of acute ischemic stroke.
    Kay R; Wong KS; Yu YL; Chan YW; Tsoi TH; Ahuja AT; Chan FL; Fong KY; Law CB; Wong A
    N Engl J Med; 1995 Dec; 333(24):1588-93. PubMed ID: 7477193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosage, anticoagulant, and antithrombotic effects of heparin and low-molecular-weight heparin in the treatment of deep vein thrombosis.
    Harenberg J; Stehle G; Blauth M; Huck K; Mall K; Heene DL
    Semin Thromb Hemost; 1997; 23(1):83-90. PubMed ID: 9156415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy of unstable angina with the low molecular weight heparins.
    Ageno W; Turpie AG
    Vasc Med; 2000; 5(4):217-23. PubMed ID: 11213233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enoxaparin and dalteparin in unstable angina: new indication. Enoxaparin: a reference treatment. Dalteparin: no better than unfractionated heparin.
    Prescrire Int; 1999 Jun; 8(41):77-80. PubMed ID: 10558446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.